New antibiotic strategy tested for dangerous infections in vulnerable cancer patients
NCT ID NCT04673175
Summary
This study tested whether a specific antibiotic (ceftolozane-tazobactam) works better than standard antibiotics to treat serious Pseudomonas infections in people with blood cancers or who have had a stem cell transplant. Participants received the antibiotic through an IV, and researchers checked if their infection improved and if they survived 30 days later. The study also included a comparison group of past patients who received standard treatments to see if the new approach was better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.